Skip to search formSkip to main contentSkip to account menu

PXD101

Known as: PXD 101 
A novel hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity. PXD101 targets HDAC enzymes, thereby inhibiting tumor… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

belinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
latent EBV and sensitize lymphoma cells to nucleoside antiviral agents Histone deacetylase inhibitors are potent inducers of gene expression in
http://bloodjournal.hematologylibrary.org/content/119/4/1008.full.html Updated information and services can be found at: (1291… 
2010
2010
Phase I pharmacokinetics and metabolic pathway of belinostat in patients with hepatocellular carcinoma.
2585 Background: Metabolic inactivation of several hydroxamic acid-derived histone deacetylase inhibitors (HDACi) involves… 
2010
2010
An open-label randomized phase II trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) compared to carboplatin and paclitaxel in patients with previously untreated…
TPS185 Background: Treatment options for patients (pts) with cancer of unknown primary (CUP) are limited; carboplatin (C) and… 
2007
2007
A phase I/II study of belinostat (PXD101) in patients with unresectable hepatocellular carcinoma
15081 Background: Hepatocellular carcinoma (HCC) is a common cause of cancer morbidity and mortality. It is a highly aggressive… 
2007
2007
Defining a set of genes dysregulated in response to the HDAC inhibitor PXD101 (belinostat)
A129 PXD101(NSC 726630) is a hydroxamate-type histone deactylase inhibitor (HDACi), which is a compound class emerging as… 
2007
2007
Activity of PXD101, an HDAC inhibitor, used alone or in combination with 5-FU in preclinical gastroesophageal studies
AACR Annual Meeting-- Apr 14-18, 2007; Los Angeles, CA 691 PXD101 is a novel hydroxamate that potently inhibits the enzymatic… 
2006
2006
Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple…
Bortezomib, a proteasome inhibitor, has been known to have in vitro and in vivo activity against multiple myeloma (MM). PXD101, a… 
2006
2006
Activity of the HDAC inhibitor, PXD101, used as monotherapy and combination therapy in preclinical NSCLC studies
Proc Amer Assoc Cancer Res, Volume 47, 2006 4743 PXD101 is a novel hydroxamate that potently inhibits the enzymatic activity… 
2005
2005
A phase I study of the histone deacetylase (HDAC) inhibitor PXD101 in patients with advanced hematological tumors
3137 Background PXD101 is a novel hydroxamate HDAC inhibitor with potent antiproliferative activity in vitro against many… 
2005
2005
Combination of Proteasome Inhibitor PS 341 (Velcade®) with Histone Acetylase Inhibitor (HDAC) PXD 101 Shows Superior Anti-Myeloma Activity and Inhibits Osteoclastogenesis.
Background: PS 341 has demonstrated activity in multiple myeloma (MM), and PXD 101 is a new HDAC inhibitor, currently being…